Nifty, Sensex slide again on Trump tariff threat and foreign selling — plus 3 stock buys for Jan 8

Nifty, Sensex slide again on Trump tariff threat and foreign selling — plus 3 stock buys for Jan 8

MUMBAI, Jan 8, 2026, 12:06 IST

  • Indian shares extended losses to a fourth session as tariff worries and foreign outflows weighed.
  • Traders watched the 26,000–26,300 zone on the Nifty after GIFT Nifty signalled a soft open.
  • Nuvama’s Aakash K Hindocha flagged ABB, Fortis and Petronet as buy ideas with targets and stop-losses.

Indian shares slipped again on Thursday, with the Nifty 50 down 0.18% at 26,093.35 and the Sensex off 0.13% at 84,847.3 by 9:55 a.m. local time, as tariff worries and foreign fund selling kept risk appetite thin. 1

The move matters because investors are heading into a key stretch of quarterly results while the market’s biggest driver has drifted back to geopolitics. Traders are watching New Delhi’s negotiations with Washington, after U.S. President Donald Trump warned of higher tariffs on Indian goods over India’s Russian oil purchases.

Foreign investors sold 15.28 billion rupees ($170.26 million) of Indian shares on Wednesday, taking January’s outflows to $694 million after record selling in 2025, provisional data showed. The U.S. has already imposed tariffs of up to 50% on Indian goods, with half of those penalties tied to Russian crude imports.

GIFT Nifty — a futures contract that tracks the Nifty 50 before India’s cash market opens — was down 40 points at 26,186.50 ahead of the session. India VIX, a gauge of expected swings, eased to 9.95, and a technical view in The Economic Times put the near-term range at 26,000–26,300; the paper also cited net foreign selling of Rs 1,528 crore versus domestic buying of Rs 2,889 crore and said the rupee rose 31 paise to 89.87 per dollar on suspected RBI intervention. 2

Fifteen of 16 sector indexes fell in early trade, with the broader small-cap and mid-cap gauges also lower. Metals led losses and IT stocks weakened; Gland Pharma climbed after U.S. approval for an eye-treatment drug, while Balaji Amines jumped after Maharashtra cleared it for industrial subsidies tied to an expansion.

“Geopolitics and global trade have cast a shadow of chronic risk aversion for equity markets,” said analysts led by Abhishek Saraf at Motilal Oswal Financial Services. The conclusion of the long-pending India-U.S. trade deal would be a key catalyst for an upside move in Indian markets, they added.

Some brokers are still hunting for trades inside the pullback. Aakash K Hindocha, deputy vice president for wealth-management research at Nuvama Professional Clients Group, said “dips below Wednesday’s low of 26060 are likely to get bought into with 26k acting as support,” and named ABB, Fortis and Petronet as buy ideas, with stop-loss levels (exit prices meant to cap losses) and targets. 3

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
NAB share price rebounds as inflation debate shifts to Jan CPI and RBA decision
Previous Story

NAB share price rebounds as inflation debate shifts to Jan CPI and RBA decision

South32 stock slips on metals pullback as ASX rises — what investors watch next
Next Story

South32 stock slips on metals pullback as ASX rises — what investors watch next

Go toTop